Introduction
The Hedgehog (Hh) signaling pathway has a pivotal function in the stromal-epithelial interactions of visceral organ development. The secreted ligand Sonic Hedgehog (Shh) activates an intracellular transduction mechanism in the target cell by binding to the plasma membrane receptor Patched (Ptc). Ptc binding relieves inhibition of another membrane protein, Smoothened (Smo) , and results in the activation of target gene transcription by members of the Gli transcription factor family. Gli1 or Gli2 proteins act as transcriptional activators. Both Ptc and Gli1 are transcriptional readouts of Gli1 and Gli2 activity, and increased transcription of Gli1 and Ptc in the target cell serves as an indicator of Hh pathway activity. Gli3 behaves primarily as a repressor of Hh target gene expression in the absence of Shh; this inhibitory action is relieved by binding of ligand and activation of the Hh pathway. Although the premier function of Hh signaling is in the developing embryo, the Hh pathway can be reactivated in adult tissues as part of the regenerative response to injury and sustained activation has been linked to tumor initiation and progression (Kelleher et al., 2006) . It is estimated that 25% of cancer deaths are associated with altered Hh signaling (Lum and Beachy, 2004) , and evidence from several studies suggests that Hh pathway activity in prostate cancer promotes tumor growth, invasion, metastasis and hormone independence (Fan et al., 2004; Karhadkar et al., 2004; Sheng et al., 2004) .
The Hh pathway has been touted as a promising target for directed chemotherapy, and Smo, Gli1 and Gli2 have been considered primary targets for anti-Hh therapeutics (Lauth and Toftgard, 2007b) . A corn lily steroidal alkaloid, cyclopamine, inhibits intracellular Hh signaling by blocking the activity of Smo and has been used as a first-generation Hh inhibitor in the treatment of localized basal cell carcinoma. Second-generation Hh inhibitors mimic the action of cyclopamine or directly block the activity of Gli transcription factors (Lauth et al., 2007) . Efforts to develop and apply anti-Hh therapeutics have been underway for several years. Progress in the preclinical testing of these agents against prostate cancer will depend on understanding of the important molecular mechanisms of Hh signaling in prostate cancer and the development and validation of an appropriate tumor model system.
The mechanism of Hh signaling in prostate cancer has been controversial. Surveys of Hh signaling in human prostate specimens revealed the presence of robust Hh signaling in both benign and malignant prostate tissue, with the finding of increased Hh signaling in advanced, metastatic disease. Tumor cell Shh expression was shown to promote the growth of human prostate cancer xenografts in mice and this was associated with increased expression of Gli1 within mouse stromal cells, suggesting a paracrine mechanism of effect (Fan et al., 2004) . Subsequent studies appeared to show the presence of autocrine signaling in human prostate cancer tissues. These studies showed that cyclopamine decreased growth of prostate cancer cells in vitro, in apparent support of an autocrine mechanism (Karhadkar et al., 2004; Sanchez et al., 2004) , but it was later shown that the inhibition of prostate cancer cell proliferation is not accompanied by the expected changes in expression of the endogenous target genes Gli1 and Ptc (Levitt et al., 2007; Zhang et al., 2007) . Further, it was shown that these prostate cancer cell lines do not respond to Shh ligand stimulation (Levitt et al., 2007; Zhang et al., 2007; McCarthy and Brown, 2008) . This is not to say that autocrine signaling does not occur in prostate cancer. There is evidence for mutational activation of the Hh pathway in a ligandindependent manner and prostate cancer cells have been shown to respond to Gli inhibitors with decreased proliferation and transcription of Gli1 and Ptc (Lauth et al., 2007) . Taken together, the published evidence suggests that Hh signaling in prostate cancer may embrace both autocrine and paracrine mechanisms.
The studies presented here were designed to rigorously examine the mechanism of Hh signaling on growth of the LNCaP xenograft tumor and then to extend those observations to elucidate the contribution of paracrine Hh signaling in human prostate cancer. They support the conclusion that activation of the Hh pathway in tumor stromal cells, achieved by either ligand-dependent paracrine signaling or ligand-independent pathway activation, is sufficient to promote tumor growth. Hh pathway activation in the tumor stroma induces expression of genes identified as Hh-regulated genes in the fetal prostate. Nine target genes, induced by Shh in the developing prostate and by Shh overexpression in the LNCaP xenograft, comprise a signature of paracrine Hh signaling that is associated with growth stimulation. In human prostate tissue, a partial recapitulation of this Hh-regulated gene expression signature is associated with cancer and the complete signature is associated specifically with tumors exhibiting a reactive stroma.
Results

Autocrine Shh signaling does not regulate tumor growth
Gli2 is the linchpin of the transcriptional response to Hh ligand. This has been shown in genetic studies (Bai et al., 2002) and in cell-based assays where deletion of the Gli2 gene was found to reduce Shh-induced target gene expression by 50-70% (Lipinski et al., 2006) . The human prostate cancer cell line LNCaP does not respond to Shh ligand or transfection with oncogenic Smo, but transfection of LNCaP cells with Gli2 induces expression of both Ptc and Gli1 (Zhang et al., 2007) . These studies point to a disruption in the canonical signal transduction mechanism upstream of Gli2 that precludes ligand-dependent pathway activation in LNCaP cells. But this mechanism leaves open the possibility of a response to Hh ligand that is not associated with Gli1 and Ptc transcription or an alternative mechanism of Hh pathway activation mediated by selective changes in the activity of Gli2. Notably, it has been reported that Gli2 protein is increased in prostate cancer cells than in normal prostate epithelium, even though Gli2 mRNA is no more abundant (Bhatia et al., 2006) . To examine these possibilities, we tested the effect of blocking the Hh pathway with a dominant negative form of Gli2. The Gli2 mutB construct was cloned from a family with clinical features of Gli2 loss of function. mutB lacks the part of the C-terminal transactivation domain and acts to prevent Hh target gene activation by Gli2 (Roessler et al., 2005) . We first showed that induction of Gli1 and Ptc expression by transient transfection of LNCaP with Gli2 was abrogated by co-transfection with mutB ( Figure 1a ). We stably transfected LNShh cells with mutB and achieved high expression without any effect on Shh, Ptc or Gli1 expression ( Figure 1b ) or proliferation in vitro (Figure 1c ). LNShh and LNShh-mutB xenograft tumors exhibited the same increased growth rate as compared to LNCaP xenografts (Figure 1d ).
Recent studies suggest the existence of a noncanonical pathway for Hh signaling that is not mediated by Smo or Gli proteins (Lauth and Toftgard, 2007a) . To test whether the acceleration of tumor cell proliferation in LNShh xenografts involves noncanonical ligand-dependent effects, we examined tumor growth and cell proliferation in chimeric xenografts made by coinjecting equal numbers of parent LNCaP (GFPÀ) and LNShh (GFP þ ) cells. The chimeric and LNShh xenografts displayed the same accelerated rate of growth as compared to the parental LNCaP xenograft. Green fluorescent protein (GFP) immunostaining revealed that the chimeric tumors were composed of a mixed population containing approximately equal numbers of LNCaP and LNShh cells (Figure 2a ), and quantitative analysis of proliferation by Ki67 staining showed that LNCaP and LNShh cells proliferate at the same rate ( Figure 2b ). From these studies, we conclude that LNCaP cell overexpression of Shh exerts a non-cell autonomous effect on proliferation.
Paracrine fingerprint
Using species-specific reverse transcription (RT)-PCR primers to examine gene expression in the human tumor cells and mouse stromal cells of LNCaP and LNShh xenograft tumors, we previously showed that expression of human Gli1 and Ptc was unchanged in LNShh tumors whereas mouse Gli1 and Ptc were both significantly increased (Fan et al., 2004) . These findings implied a paracrine mechanism of action in which mouse stromal cells respond to Shh secreted by LNShh tumor cells and exert reciprocal effects that promote tumor cell proliferation. The expression of several previously identified Shh target genes (Sfrp1, Cyclin D1, Bcl-2, FGF-10, BMP-4, FoxA1, VEGF and IGF-II) was not different in the stroma of LNCaP and LNShh tumors (data not shown). Hh target genes vary between tissues and we therefore developed a strategy to identify Hh-regulated stromal genes in the prostate. As a first step, we made biclonal xenografts by coinjecting LNCaP cells with the immortalized urogenital sinus mesenchymal cell line UGSM-2 (Shaw et al., 2006) . These tumors grow at the same rate as the canonical LNCaP xenografts; histological examination revealed a stroma composed of both UGSM-2 cells and resident host stromal cells (data not shown). When LNShh cells were coinjected with UGSM-2, the biclonal xenografts grew at a faster rate than LNCaP þ UGSM-2 xenografts, replicating the growth effect of Shh overexpression in the canonical xenografts ( Figure 3a ). We then performed a microarray analysis of genes activated by Shh treatment of UGSM-2 cells as part of our studies of prostate development and validated 19 Shh-regulated genes in the embryonic day 16 (E16) mouse UGSM (Yu et al., 2009 ). Expression of these 19 genes was examined in the stroma of LNCaP þ UGSM-2 and LNShh þ UGSM-2 biclonal xenograft tumors using species-specific RT-PCR. Nine genes exhibited significantly different expressions in the LNShh xenograft stroma consistent with regulation by Shh ( Figure 3b ). The nine genes are as follows: a disintegrin and metalloproteinase domain 12 (ADAM12), angiopoietin-4 (Agpt4), breast-and kidney-expressed chemokine (BRAK) or CXCL14, fibrillin-2 (Fbn2), fibroblast growth factor-5 (Fgf5), hairy and enhancer of split 1 (Hes1), hydroxysteroid 11-b dehydrogenase 1 (HSD11b1), insulin-like growth factor-6 (Igfbp6) and tissue inhibitor of metalloproteinase 3 (Timp3). Hhregulated expression of these nine genes was postulated to be a 'fingerprint' of tumor stroma in which paracrine signaling promotes tumor growth.
Activated stromal Shh signaling is sufficient to accelerate tumor growth To verify that activation of Hh target gene expression in tumor stromal cells is sufficient to accelerate tumor growth, we derived UGSM cell lines from Gli3 mutant mouse embryos. The Gli3xt is a spontaneous missense mutation that abrogates Gli3 activity (Schimmang et al., 1993) and results in basal activation of the Hh pathway independent of Shh ligand (Lipinski et al., 2006) . We bred the Gli3xt mutation onto an INK4a mutant background. The INK4a mutation allows spontaneous immortalization of mesenchymal cells. We then harvested mesenchymal cells from the embryonic prostate of Gli3xt/xt or Gli3wt/wt littermates. Basal expression of Gli1 in Gli3xt/xt cells is elevated to a level comparable to the level of Gli1 expression induced by Shh in wild-type cells (Figure 4a ). We then generated biclonal xenografts containing LNCaP cells and either Gli3xt/xt or Gli3wt/wt cells. Xenografts containing Gli3xt/xt cells grew significantly faster than xenografts containing Gli3wt/wt cells ( Figure 4b ). These observations show that UGSM cells with constitutive activation of Hh target gene transcription accelerate tumor growth in the absence of Hh ligand.
Fingerprint in human tumors
Our previous quantitative analysis of Hh pathway activity revealed the unexpected finding of equivalent robust Shh and Gli1 expression in both localized prostate cancer and benign prostate tissue. This finding prompted us to speculate that the effect of paracrine Hh signaling on cell proliferation may depend on the stromal response to Hh ligand. We have found in the developing prostate that Hh signaling promotes epithelial proliferation in the fetal prostate but inhibits epithelial proliferation in the postnatal prostate (unpublished observations). When we compared expression of Shh, Gli1, Ptc and the nine genes of the fingerprint in specimens of clinically derived prostate cancer (n ¼ 18) and benign prostate tissues (n ¼ 26), neither Shh nor Gli1 expression was significantly higher in cancer ( Figure 5a ), and of the nine target genes only BRAK exhibited significantly increased expression in cancer, a finding previously reported (Schwarze et al., 2005) . We then performed correlation analysis to identify genes that share a common regulatory pathway or function (Stuart et al., 2003; Gustin et al., 2008) with Hh signaling. We examined the correlation of expression among Shh, Gli1, Gli2, Ptc and the nine genes of the stromal fingerprint in all specimens examined and compared these findings in subgroups of interest. Analysis of all tissues, regardless of histopathology, showed that the expression of Shh, Gli1, Gli2 and Igfbp6 was significantly correlated in all pair-wise combinations of these genes ( Supplementary Figure 1 ). Analysis of Indian Hedgehog (Ihh) expression showed no correlation with Gli1 or Gli2, indicating that Gli1 and Gli2 expression relates specifically to the expression of Shh. Correlation analysis was then performed separately when tissues were grouped as benign or cancer. For the benign samples, there was clustering of Shh, Gli1, Gli2, BRAK and Igfbp6 expression. For the cancer samples, there was clustering of Shh, Gli1, Gli2, Igfbp6, ADAM12, Agpt4, HSD11b1 and Timp3 (Figure 5b) . Remarkably, the expression of these genes in cancer was significantly correlated in all pair-wise combinations and all genes were positively correlated (Supplementary Figure 2 ). The clustering of Shh, Gli1, Gli2 and Igfbp6 shows Shh-regulated gene expression is present in benign and cancerous tissue, but the unique clustering of ADAM12, Agpt4, HSD11b1 and Timp3 with Shh and Gli1 in cancer suggests an altered stromal response to Shh in stroma associated with cancer vs benign epithelium.
Reactive stroma in prostate tissue
We speculated that further characterization of the tumor stroma would isolate the gene expression networks. Myofibroblasts are stromal cells that express both fibroblast (vimentin) and smooth muscle markers (smooth muscle actin, SMA), exhibit a unique ultrastructure associated with extracellular matrix remodeling, and are found in developing tissues, granulation tissues and neoplasia (Tuxhorn et al., 2001) . Myofibroblasts are found in both the developing mouse and human prostate (Bierhoff et al., 1997) ; they are generally absent from the adult mouse prostate but are present to variable degrees in the adult human prostate.
In the human prostate, myofibroblasts appear to be especially abundant in areas of malignant transformation, where their presence has been considered a hallmark of a reactive stroma (Tuxhorn et al., 2001) . Our studies revealed that myofibroblasts are a consistent feature of both LNCaP and LNShh xenograft tumors ( Supplementary Figure 3) . Because the UGSM-2 cell line that was used to identify stromal Hh target genes exhibits a myofibroblast phenotype, we examined the possibility that the nine-gene fingerprint genes identified in the myofibroblastic xenografts is specific to reactive stroma. The same tissues analyzed by RT-PCR for the correlation studies described above were co-stained for SMA and vimentin. Myofibroblasts, which stain for both SMA and vimentin, were present in varying degrees in both benign and malignant tissue (Supplementary Figure 3 ). Immunostaining was scored in blinded manner and the stroma was categorized as reactive or nonreactive based on the abundance of myofibroblasts. Thus, the 44 tissue samples were divided into 4 groups: 9 tumor reactive, 9 tumor nonreactive, 15 week 4
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Xenograft Tumor Growth benign reactive and 11 benign nonreactive. The reactive score does not correlate with Gleason score or stromal density ( Supplementary Figure 4 ). There were no significant differences in target gene expression between any of the four groups, except for BRAK as previously described (Supplementary Figure 5) . Correlation analysis showed that Shh expression correlates with Gli1 and Gli2 in all four groups. The striking finding is the clustering of Shh, Gli1, Ptc and all nine genes of the complete fingerprint uniquely in the tumor reactive samples (Figure 6a ). Analysis of proliferation in these tissues showed that proliferation is highest in the tumor reactive group (Figure 5c ).
Discussion
A recently published study revealed increased Hh pathway activity in a variety of tumor types (Yauch et al., 2008) , and there is evidence that metastatic and androgen-independent prostate cancer exhibit markedly elevated pathway activity (Fan et al., 2004; Karhadkar et al., 2004) . However, a meticulous comparison of Hh signaling in localized prostate cancer and benign control tissues did not show consistently increased pathway activity in cancer; rather, this study revealed robust Shh expression and Hh pathway activity in both benign and malignant tissues (Fan et al., 2004) . These findings were recapitulated here with an entirely new set of cancer and benign specimens. Active signaling is present in both benign and cancer tissues, evidenced by the consistent correlation between Shh and Gli1 expression. The results presented here address and definitively answer several critical questions raised by these observations with respect to the action of Shh in prostate cancer. First, we show that action of Shh on carcinoma cells (autocrine signaling) is not necessary for acceleration of tumor cell proliferation. Rather, secreted Shh induces a nonautonomous paracrine signaling network in tumor stroma that stimulates growth. Second, we show that Hh pathway activation in a myofibroblast component of the tumor stroma is sufficient to accelerate tumor growth. The accelerating effect of Gli3xt/xt myofibroblast cells on tumor growth signifies that the growthaccelerating effect of Shh overexpression in the LNShh tumor does not depend on a direct effect of Shh ligand on other components of the stroma. This is critical because both endothelial and immune cells have been identified as targets of Hh signaling. Finally, we have identified a transcriptional signature of Hh signaling in the LNShh xenograft, related to the transcriptional readout of the fetal prostate mesenchyme, that is faithfully recapitulated specifically in human prostate cancers exhibiting a reactive stroma. Insight into the mechanisms determining the stromal mediation of Hh signaling will be crucial to evaluating the utility and efficacy of Hh inhibitors in the treatment of prostate cancer. Karhadkar et al. (2004) showed that Hh blockade by the Smo inhibitor cyclopamine could inhibit xenograft tumor growth, and recent studies suggest that the inhibition of growth results from blockade of paracrine Hh signaling (Yauch et al., 2008) . This is consistent with the studies presented here and our previous work identifying paracrine signaling as the primary Hh mechanism in localized prostate cancer (Fan et al., 2004) . Studies attempting to correlate a clinical response to Hh inhibitors with events at the cellular level will need to examine the effect of Hh blockade on pathway activity in the tumor stroma. The data reported here provide a gene expression signature that is a putative biomarker of growth promotion and suggest that tumors with a reactive stroma, which exhibit this signature, are more likely to exhibit a favorable clinical response to Hh inhibitors.
Canonical Hh signaling involving the tumor stroma may not be the only Hh mechanism stimulating human prostate cancer progression. Indeed, there is evidence to suggest that noncanonical activation of autocrine Hh pathway activity may occur, especially in advanced prostate cancer. Hh pathway activity resulting from mutational activation in the Hh signal transduction mechanism or by aberrant pathway activation could be unresponsive to Smo inhibition and require alternate therapeutic approaches (Sheng et al., 2004; Lauth and Toftgard, 2007b) . Notably, recent studies showed that Gli1 inhibitors GANT61 and GANT58 could be used to inhibit proliferation of tumor cells in which such Hh pathway activation has occurred (Lauth et al., 2007) .
Previous studies have highlighted the potential significance function of myofibroblasts in prostate cancer stroma. Rowley, Ayala and colleagues (Tuxhorn et al., 2002; Yanagisawa et al., 2008) have shown that myofibroblasts stimulate growth of xenograft tumors and that the accumulation of myofibroblasts in human prostate cancer is negatively correlated with tumor-free survival. Whereas Shh-accelerated growth of LNShh xenografts was associated with increased expression of the nine Hh target genes, we did not observe increased expression of these target genes in human prostate cancer. Efforts to perform a meta-analysis of this gene network using the microarray data sets on the cancer profiling database Oncomine ( 2007a, b) was stymied by the absence of Gli1, Ptc and several of the target genes from the data sets. What we did observe from analysis of our own tissue set was a striking and statistically powerful correlation between expression of Shh and the tumor-fingerprint target genes, most strikingly in tumors with a reactive stroma. The best explanation for this finding is the emergence of a stromal phenotype in cancer that resembles the fetal mesenchyme and results in a coordinate regulation of target genes that mimics the fetal transcriptional response to Shh. Since expression of these genes is not upregulated in cancer, it could be argued that an effect of Hh signaling on tumor growth is unlikely. Recognizing the validity of this argument, we postulate that the emergence of coordinate target gene regulation in the tumor stroma is a characteristic of a mesenchymal/stromal phenotype that responds to Hh ligand by exerting growth-promoting activities that stimulate tumor cell proliferation. 
Materials and methods
Xenografts
Xenograft tumors were generated in adult male CD-1 nude mice. LNCaP, LN-GFP or LN-Shh (2 Â 10 6 ) were mixed with 0.5 Â 10 6 INK4 cells and 50% Matrigel and injected subcutaneously on the flanks of mice. For 1:1 mix tumors, 1 Â 10 6 LNCaP and LN-Shh were combined and injected subcutaneously as described above. LN-GFP and LN-Shh stably express GFP or GFP þ Shh, respectively (Fan et al., 2004) . Tumors were measured weekly with calipers, and tumor volume was calculated as the volume of a spheroid using the formula: Vol ¼ L Â W Â H Â 0.5236 (Janik et al., 1975) .
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were dewaxed, rehydrated and processed for 10 min in citrate buffer for antigen retrieval. GFP was stained by incubation with anti-GFP (AB3080; Chemicon, Temecula, CA, USA) diluted to 4 mg/ml in PBC þ 10% (goat or donkey) serum þ 1% bovine serum albumin overnight at 4 1C. Human Ki67 was stained by incubation with prediluted Ki67 antibody (08-0192, Zymed Laboratories, South San Francisco, CA, USA) for 1 h at room temperature. SMA was stained by incubation with 1:200 anti-SMA ascites (A2457; Sigma-Aldrich, St Louis, MO, USA).
In human sections, vimentin was stained by incubation with 1:100 anti-vimentin (AB1620; Chemicon). In mouse sections, vimentin was stained by incubation with 1:100 anti-vimentin (sc-7557; Santa Cruz, Santa Cruz, CA, USA). The primary antibodies were detected by incubation with goat or donkey anti-goat, anti-rabbit or anti-mouse conjugated with Alexa 488 or Alexa 555 (Molecular Probes, Eugene, OR, USA) at 5 mg/ml for 45 min at room temperature. Slides were mounted with Vectashield Hardset þ DAPI mounting media (Vector, Burlingame, CA, USA) and imaged using an Olympus model BX51 fluorescent microscope and Spot Advanced software version 3.5.2. In xenografts, GFP and Ki67 and total tumor cells were counted in 10 random Â 200 fields of view. Ki67 staining is human specific, so proliferation of mouse stromal cells is not included. In patient tissues, Ki67, SMA and vimentin were counted in five random Â 200 fields of view. For each sample, the frequency of myofibroblasts was determined by rating myofibroblasts/total stromal cells on the following scale: 1, no myofibroblasts; 2, 1-5% myofibroblasts; 3, 5-25% myofibroblasts; 4, >25% myofibroblasts. The frequency of myofibroblasts was determined for each of five random fields of view and totaled for each section to give scores that vary between 5 and 20. Samples with a score of 4-9 were ranked as nonreactive and samples with scores 10-20 are ranked as reactive. Analysis was performed in a blinded manner so the analyst did not know of the benign, tumor, reactive or gene expression nature of the samples. The ranking of samples as reactive vs nonreactive was determined before quantitative or correlation analysis of gene expression was performed.
Isolation of UGSM cells
Generation of UGSM-2 cells was described in a previous paper (Shaw et al., 2006) . To generate INK4aÀ/À, Gli3xt/xt mice, INK4aÀ/À mice were bred to Gli3xt/ þ mice and then backcrossed to INK4aÀ/À mice to generate INK4aÀ/À, Gli3xt/ þ mice. INK4aÀ/À, Gli3xt/ þ mice were mated and embryos collected at E16. The day of vaginal plug was counted as E0. Resulting embryos from a single litter included INK4aÀ/À, Gli3 þ / þ ; INK4aÀ/À, Gli3xt/ þ ; and INK4aÀ/À, Gli3xt/xt. UGSM from male embryos was collected and cultured in the same manner as UGSM-2 cells. Embryo tissue was used for genotyping according to established protocols (Hui and Joyner, 1993) . Clonal populations were isolated by ring cloning from the mixed primary cell population.
Gene expression analysis
RNA was isolated from cultured cells and tumors using RNeasy mini kit (Qiagen, Valencia, CA, USA) with optional on-column DNase digestion to eliminate contaminating DNA. Total RNA (1 mg) was reverse transcribed to generate cDNA using M-MLV reverse transcriptase (Invitrogen). Relative mRNA quantity was determined by real-time RT-PCR using iCycler instrumentation and software (Bio-Rad, Hercules, CA, USA).
Human prostate samples
Paired prostate cancer/benign prostate tissue specimens were provided by the Tissue and Serum Repository (Kansas Cancer Institute, University of Kansas Medical Center, Kansas City, KS, USA). After removal of the prostate from men undergoing radical prostatectomy for clinically localized prostate cancer, core biopsies were performed of presumed tumor and the equivalent site on the contralateral side of the specimen. Each sample was divided and snap frozen or formalin fixed/ paraffin embedded. Of the 44 specimens processed in this way, tumor and benign tissue from the same patient were confirmed by histological examination. Some samples from the same patient are both benign or both tumor. The samples include 18 tumors and 26 benign tissues. Of these, 13 sets are matched. The institutional review boards of the University of Wisconsin-Madison and Kansas University Medical Center approved all procedures for tissue acquisition and analysis.
Statistics
We analyzed tumor growth rate by obtaining slopes. These were obtained by calculating the difference between final and initial tumor volumes, and then dividing by the intervening number of weeks: (V n -V 0 )/n, where V 0 denotes the tumor volume (in mm 3 ) when it first becomes apparent, V n denotes the tumor volume n weeks later and n is the number of weeks between tumor appearance and the end of the experiment or the week in which the animal needed to be killed, whichever occurred earlier.
Tumors with one or more of the following conditions were excluded from the analysis: those with a final volume of less than 100 mm 3 , those that contracted (that is, final volume less than initial volume), those that were undetectable in any given week after initial establishment and those with a slope less than 10 mm 3 per week. One-way analysis of variance (ANOVA) was used to test for differences in growth rate (slope) due to treatment; slopes within a given animal were considered independent. If the overall F-test was significant (Po0.05), pair-wise comparisons between treatments were examined. This procedure is equivalent to Fisher's protected least-squares differences (LSD). To better meet the assumptions of ANOVA, we considered rank and logarithmic transformations of the original data. Slopes for tumor growth seemed to have a slightly positive skew distribution. A logarithmic transformation did not improve matters, so ANOVA was performed on the raw slopes. We analyzed differences in gene expression by comparing the average GAPDH normalized value for each gene using a t-test assuming unequal variances. To examine the degree of linear association in expression between pairs of genes, we obtained Pearson's correlation coefficient. This was conducted (1) for all of the samples together, (2) for the tumor and the benign samples separately and (3) for each of the four tumor-reactivity groups (benign/tumor vs reactive/nonreactive) separately. ANOVA was used to test for differences in gene expression between the four tumor-reactivity groups. If significant differences were found, pair-wise comparisons were obtained (Fisher's protected LSD).
To better meet the assumptions of ANOVA, we analyzed the natural logarithms of expressions, after having added 1EÀ4. Po0.05 as the criterion for statistical significance; all hypothesis tests were two sided. There was no adjustment for multiple testing. Both the correlation analysis and ANOVA treated the observations as independent. All the statistical graphics and computations were obtained in R for Windows, version 2.5.0 patched (2007-02-04 r40647, R Development Core Team, 2005, R Foundation for Statistical Computing, Vienna, Austria).
